Statement: Zantac (ranitidine) litigation – Kasza case

GSK plc (LSE/NYSE: GSK) welcomes the plaintiff’s voluntary dismissal of the next Zantac case (Kasza), which was scheduled to start trial in Illinois state court on 10 June 2024. GSK did not settle Ms. Kasza’s claim and has not paid anything in exchange for the voluntary dismissal.

Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.

GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q1 Results for 2024.